Last modified: January 9, 2010
Offices[edit]
People[edit]
Web Presences[edit]
- Biotech & Life Sciences
- Pharmaceutical
Industries[edit]
Parent Company[edit]
Acquisitions / Subsidiaries[edit]
Paid Sources[edit]
Keywords[edit]
|
|
Description[edit]
CoMentis, Inc. is headquartered in South San Francisco, with research operations in Oklahoma City. The company is engaged in the discovery and development of small-molecule Drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders.
The company has two fundamental technology platforms: (i) aspartic protease inhibitors, including beta-secretase inhibitors for Alzheimer’s disease; and (ii) nicotinic acetylcholine receptor (nAChR) agonists and antagonists for the treatment of angiogenesis mediated diseases and cognitive disorders.
CoMentis currently has three product development programs in its pipeline: ATG-3, a topical (eye drop) anti-angiogenesis compound for neovascular AMD in Phase II development; CTS-21166, an orally active beta-secretase inhibitor for Alzheimer’s disease in Phase I development; and a series of next generation ?7 nAChR agonists in preclinical development.
Innovation[edit]
Activities[edit]
| Jobs by SimplyHired |
- No jobs were found for this particular company. Please visit the job board to search for more.
| CoMentis Job Trends | CoMentis Jobs |
- Biotech Showcase 2010 - Presenting Companies (3 subscribers)
This Company is Being Watched in
Recent Updates |
|---|
| CoMentis has been added to the Ecosystem. |